Methods and pharmacological agents for increasing expansion, engraftment or immune output of human hematopoietic stem cells in transplantation and disease settings

Abstract

The present application relates to methods for expanding hematopoietic stem cells (HSC) and/or hematopoietic progenitor cells (HPC) ex vivo and/or in vivo. The methods comprise culturing the HSCs and/or HPCs in the presence of a selective 5-Hydroxytryptamine Receptor 1F (HTR1F) agonist and/or of a Thyroid Hormone Receptor Beta (THRB) agonist, and/or in an air-liquid interface (ALI) culture system. The expanded HSCs and/or HPCs, which maintain engraftment and immune reconstitution properties, may be administered to subjects suffering from various diseases including cancer, immunodeficiencies, myelodysplastic syndrome (MDS) or anemia. The present application also relates to the use of HTR1F and/or THRB agonists for stimulating HSC and/or HPC expansion, and for increasing the number of immune cells or for reconstituting the immune system, in vivo.

Dependencies are inferred from the claim text.